Institutional members access full text with Ovid®

Share this article on:

Fecal Calprotectin Levels Predict the Clinical Course in Patients With New Onset of Ulcerative Colitis

Lasson, Anders MD*,†; Simrén, Magnus MD, PhD; Stotzer, Per-Ove MD, PhD; Isaksson, Stefan MSc; Öhman, Lena PhD; Strid, Hans MD, PhD

doi: 10.1097/MIB.0b013e31827e78be
Original Clinical Articles

Background: The clinical course of ulcerative colitis (UC) is unpredictable. During recent years, the ability of fecal biomarkers to predict relapse in inflammatory bowel disease has been evaluated. The objective of this study was to assess fecal calprotectin (FC) as a predictor of disease recurrence in patients with new onset of UC.

Methods: Sixty-nine patients were included. After the initial treatment, patients were followed up after 3 months and then yearly for 3 years. The prognostic role of FC 3 months after the initial therapy was evaluated.

Results: The FC levels 3 months after the diagnosis were higher in patients experiencing a relapsing disease course compared with those with a mild disease course during 1 year (median, 263; interquartile range [IQR], 100–634 μg/g versus median, 102; IQR, 38–225 μg/g; P = 0.009) and 3 years of follow-up (median, 280; IQR, 102–622 μg/g versus median, 118; IQR, 39–219 μg/g; P = 0.01). The area under the receiver operating characteristic curves using calprotectin to predict a relapsing disease course during 1 year and 3 years were 0.69 (95% confidence interval, 0.56–0.82) and 0.70 (95% confidence interval, 0.57–0.83), respectively. In the Kaplan–Meier survival analysis, a FC level >262 μg/g was associated with an increased risk of a relapsing disease course during the study period (P = 0.003). In logistic regression analysis, only FC and age were found to be independent predictors of having a relapsing disease course.

Conclusions: Levels of FC 3 months after the initial therapy in patients with new onset of UC predict the disease course over the following years, and they are of value in the clinical management of these patients.

Article first published online 31 January 2013

*Department of Internal Medicine, Södra Älvsborgs Sjukhus, Borås, Sweden

Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Reprints: Anders Lasson, Department of Internal Medicine, Södra Älvsborgs Sjukhus, 501 82 Borås, Sweden (e-mail: anders.lasson@vgregion.se).

Supported by grants from the Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland.

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website